Condition: Small Cell Lung Cancer · Advanced Solid Malignant Tumor · Sponsor: Chipscreen Biosciences, Ltd.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
This description comes directly from the study's public registry record.
Zhijian Li, MD · 732-584-6269 · zhijian_li@chipscreen.com
Liz Wieland · Elizabeth_Wieland@chipscreen.com
Always discuss trial participation with your own doctor first.
| California Cancer Associates-Encintas | Encinitas, California, United States | Recruiting |
| Providence/St. Joe Cancer Institute/Crosson Cancer Institute | Fullerton, California, United States | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| Dana Farber Cancer Institue | Boston, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas, Nevada, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
| OU Health | Oklahoma City, Oklahoma, United States | Recruiting |
| Sarah Cannon Research Center | Nashville, Tennessee, United States | Recruiting |
| North Houston Cancer Clinics | Huntsville, Texas, United States | Recruiting |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05271292